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Multiple sclerosis is a complex and multifactorial neurological disease, and nutrition is one of the environmental factors possibly
involved in its pathogenesis. At present, the role of nutrition is unclear, and MS therapy is not associated to a particular diet. MS
clinical trials based on speciﬁc diets or dietary supplements are very few and in some cases controversial. To understand how diet
can inﬂuence the course of MS and improve the wellness of MS patients, it is necessary to identify the dietary molecules, their
targets and the molecular mechanisms involved in the control of the disease. The aim of this paper is to provide a molecular basis
for the nutritional intervention in MS by evaluating at molecular level the eﬀect of dietary molecules on the inﬂammatory and
autoimmuneprocesses involved in the disease.
1.TheEtiopathogenesisofMultipleSclerosis:
ADisease withSigniﬁcant
NeurologicalDisability inYoungAdults
Multiple sclerosis (MS) is a chronic, demyelinating disease
of the Central Nervous System (CNS) in young adults [1].
It is generally accepted that MS is an inﬂammatory and
autoimmune disease, characterized by blood brain barrier
(BBB) disruption, perivascular inﬂammation, axonal and
oligodendrocyte injury, and breakdown of the myelin sheath
[2].Inparticular, autoreactiveCD4+ Tcells, directedtowards
the myelin sheath, pass through the BBB and together with
macrophages and microglial cells degrade the myelin sheath
[3]. Mounting evidences suggest the involvement in MS
pathogenesis of other adaptive immune cells, such as Th17
cells and B lymphocytes, and innate immune cells, such as
dendritic cells, natural killer T cells, and resident microglia
[4]. Another pattern of both myelin and oligodendrocyte
damage is mediated by antibodies or complement activation
[5]. MS is also considered a neurodegenerative disease, with
axonal damage occurring very early in the course of the
disease [6].
MSisa complex,heterogenousand multifactorial disease
with unknown etiology. Dysregulation of the immune
response, genetic predisposition and environmental factors
(infectious and/or nutritional) are possible causative agents,
but none of these factors alone can explain its origin [7, 8].
Environmental factors act at a prodromal stage for the
disease, long before that MS becomes clinically evident,
and for this reason their causal pathways are diﬃcult to
determine [9].
It has been suggested that the persistence of particular
viruses, in particular the Epstein-Barr virus [10–12], the
humanendogenousretroviralfamilyW(HERV-W)elements
[13, 14], other microbial agents, or toxins may represent a
causative condition for MS in genetically suited individuals.
However, there are no data yet concerning the direct
involvement of a speciﬁc virus in MS, and the relevance
of viral infection could be ascribed more to the age and
persistence of infection rather than to a particular virus [9].
On the contrary, the uneven geographical distribution
of the disease and the inﬂuence of migration in young age
on the course of MS, strongly suggest a relevant role of
noninfectious environmental factors such the nutritional
habits and duration of exposure to the sunlight.2 Autoimmune Diseases
According to the 2008 MS Atlas of the World Health
Organization (WHO) and the Multiple Sclerosis Inter-
national Federation (MSIF)—downloaded from http://
www.who.int/mental health/neurology/en/—MS is indeed
prevalent in the more developed Western countries furthest
from Equator [15, 16]. If the genetic background is not
the discriminating element, susceptibility to MS might be
then determined by the high-fat/high-carbohydrate and
hypercaloric “Western” diets, typical of countries with high
incomes, rather than by microbial infections. On the other
hand, latitude and reduced sun exposure might inﬂuence
the availability of vitamin D.
The aim of this short review is to furnish a molecular
basis for a nutritional intervention in MS. This is an
important task because the relevance of nutrition in MS
has not been established yet, and studies on the relationship
between diet and MS are very few [17–21]. At present,
MS therapy is not associated to a particular diet, but the
majority (about 70%) of MS patients try complementary
and alternative medicine (CAM) treatments, often without
informing their physician [22–24].
On the other hand, the suggestion of a particular diet
might be not suﬃcient. To demonstrate the inﬂuence of
nutrition on MS, it is necessary to assess at the molecular
level the safety and the eﬀectiveness of nutritional inter-
ventions, including the administration of speciﬁc dietary
supplements. In other words, we need to identify the
dietary molecules able to inﬂuence the course of the disease,
their targets in the cell, and the molecular mechanisms
involved.
2.The Impact ofDietary Moleculeson
CellMetabolism
The question arises as to whether and how dietary molecules
exert their inﬂuence on cell activity. First ofall, cells certainly
havethe necessary machinery toadapt themselves to changes
in their environment, and changes in content and type of
dietarymoleculesarethemostcommonovertime(Figure 1).
Fundamentally, the molecular mechanisms by which
dietary molecules can inﬂuence the performance of our
organism in health and disease are those primarily involved
in the control of metabolism and energy homeostasis.
There are three main types of control of cell activity
that can be exerted by food molecules: (1) direct binding
to key regulatory enzymes (allosteric modulation); (2)
posttranslational modiﬁcations of enzymes or proteins in
general (proteolytic cleavage, or enzyme phosphorylation,
glycosylation,methylation,acetylation...);and(3)modiﬁ-
cationoftranscriptional regulation aﬀectingenzyme/protein
expression [25].
The inﬂuence of dietary molecules on cell activity is
certainly very complex and involves a number of targets and
multiple and intricate signaling pathways in the cell.
Targets and metabolic pathways are depicted in the
simpliﬁed scheme of Figure 2.O nt h el e f t ,l o wi n t a k eo f
nutrients, calorie restriction or fasting, and physical exercise
upregulate oxidative metabolism and metabolic rate to
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Figure 1: Cells are integrated networks constantly responding
to environmental stimuli. The ability to recognize changes in
environmentalconditionsandtoadaptthemselvestothosechanges,
is essential for the viability of cells, and changes in quality and
quantity of dietary molecules are the most frequent in the course
of the day.
match energy demand. On the right, high intake of energy-
richnutrientsupregulatestheanabolicpathways,lipogenesis,
cell growth, cell diﬀerentiation and proliferation, as well as
proimatory events.
The switch between catabolism and anabolism is deter-
mined by speciﬁc sensors that allow the cells to adapt
themselves to changes of nutrients in their surround-
ing environment shifting their metabolism either to the
catabolic (Figure 3) or to the anabolic pathways (Figure 4).
These sensors are ligand-dependent, multidomain nuclear
receptors, transcription factors, and enzymes. Upon activa-
tion by binding of lipids, cholesterol derivatives, glucose,
vitamins, hormones or antioxidants, transcription factors
bind to DNA and regulate gene expression and nutrient
metabolism.
Among the most important metabolic nuclear recep-
tors there are the peroxisome proliferator-activated receptors
(PPARs) [http://ppar.cas.psu.edu]a n dt h eliver X receptors
(LXRs).Bothcompetewithretinoid X receptor isotypesα,β,γ
(RXRs) to form active heterodimers and are involved, but
in diﬀerent way, in the regulation of fatty acid metabolism
(Figure 2).
PPAR isotypes α, β/δ, γ function as lipid sensors and
respond to the increase of fatty acids (and in particular of
oxidized fatty acids) by upregulating the transcription of
genes involved in catabolism, in particular fatty acid beta-
oxidation in mitochondria and peroxisomes [26, 27].
Other important metabolic sensors involved in catab-
olism are the enzymes Sirtuins, a family of seven NAD+-
dependent deacetylase enzymes [28] and the AMP kinases
(AMPK) [29, 30]. The cross talk between PPAR, AMPK and
sirtuins (SIRT), induces mitochondrial biogenesis and fatty
acid oxidation [28, 31].
Figure 4, and the right side of the panel in Figure 2
show the transcription factors and enzymes involved in lipo-
genesis. LXRs are lipogenic transcription factors activated
by the cholesterol derivatives oxysterols and glucose [32].
LXRsfacilitate thesynthesis offatty acidsand triacylglycerolsAutoimmune Diseases 3
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Figure 2:Schematic representation ofbiologicalresponses tonutrients andcellular outcomes. Inﬂuence of somenatural dietary compounds
andsomecommondrugs oncelltranscriptionalactivityinmetabolismandinﬂammation.PPAR:peroxisomeproliferatoractivated receptor;
LXR: liver X receptor; RXR: retinoid X-receptor; NF-κB: nuclear transcription factor-κB; SREBP: steroid regulatory element-binding
protein; ChREBP: carbohydrate responsive element-binding protein; Sirtuins: SIRT-1/2 deacetylating enzyme; AMPK: AMP Protein Kinase;
MMP: metalloproteinase; VEGF: vascular endothelial growth factor; TNF: tumor necrosis factor; ROS: reactive oxygen species; ICAM-1:
intercellular adhesion molecule: VCAM-1: vascular adhesion molecule; n-3 PUFA, omega-3 polyunsaturated fatty acids.
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Figure 3: Enzymes, hormones, and transcription factors involved
in catabolism. PKA: protein Kinase A, cAMP dependent. AMPK: 5 
AMP-activated protein kinase.
through the activation of the steroid regulatory element-
binding protein 1c (SREBP-1c), while inhibiting SREBP-2
and thereby the synthesis of cholesterol. LXRs also activate
the carbohydrate response element binding protein (ChREBP),
which regulate metabolic gene expression to convert excess
carbohydrate into triglyceride rather than glycogen.
In conclusion, the switch between catabolism and
anabolism is determined by the choice of the RXR binding
partner, either PPAR (catabolism) or LXR (anabolism).
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Anabolism SREBP-1c
NF-κB
Figure 4:Enzymes,hormonesandtranscriptionfactors involvedin
anabolism.
3.The Impact ofDietary Molecules
onInﬂammation
The link between the above transcription factors and the
nutrients explain how cells regulate energy homeostatis and
respond to changes in nutritional status, but represents also
the molecularkeyto understand hownutrients caninﬂuence
the course of chronic inﬂammatory diseases, as they can also
downregulate the proimatory transcription factors.4 Autoimmune Diseases
The key inﬂammatory transcription factors involved in
the inﬂammatory responses are shown at the center of
Figure 2. They are the Activator Protein-1 (AP-1) and the
Nuclear transcription Factor k of activated B cells (NF-
κB). In particular, NF-κB is activated by ROS, endotoxins,
inﬂammatory stimuli, X-rays, carcinogens and viruses, dis-
sociates from its inhibitory proteins IκB, and translocates
to the nucleus, where it induces the expression of more
than 200 genes related to cell proliferation, metastasis, and
inﬂammation.
In MS, AP-1 and NF-κBa r ea c t i v a t e d[ 33]a n ds p e c i ﬁ c
enzymes and their products involved in inﬂammation are
overexpressed: matrix metalloproteinase-9 (MMP-9, gelati-
nase B), plasminogen activators, phospholipase A2 (PLA2),
cyclooxigenase-2(COX-2)andprostaglandins,lipoxygenases
(LOX) and leukotrienes, Th1 cytokines, IL-1 and TNF,
adhesion molecules, reactive oxygen species (ROS), as well
as nitric oxide synthase (NOS) and nitric oxide. As a con-
sequence, inﬂammation, oxidative stress, and angiogenesis
are increased or sustained. Oligodendrocytes, neurons and
the myelin sheath are injured. Microglial cells sustain the
neuroinﬂammatory processes.
At the molecular level, the links between metabolism
and inﬂammation are given by the nuclear receptors PPAR
and LXR. Besides their role as regulators of energy home-
ostasis and metabolic diseases, PPAR and LXR isotypes
also have an important role in inﬂammatory pathways and
immunological regulation. PPARs exert antiinﬂammatory
eﬀects by inhibiting NF-κBa n dA P - 1[ 34]a n da r ea b l et o
integratemetabolicandinﬂammatory signalingbyinhibiting
inﬂammatory gene expression [35].
4.Nutrientsto AvoidinMS
4.1. Animal Fat. In principle, MS patients should avoid the
intake of food containing molecules that are potentially
harmful over time and should prefer healthy food containing
those molecules that can improve their well-being by lower-
ing, for example, the extent of inﬂammation.
Among the dietary factors that have been considered
most frequently for their deleterious inﬂuence on MS are
saturated fatty acids of animal origin (found in whole milk,
butter,cheese,meat,sausages...).In1950 Swank suggested
that the consumption of saturated animal fat is directly
related to the frequency of MS [36]. In 2003, Swank and
Goodwin reported that restriction of saturated fat induces
remission of the disease and produces beneﬁcial eﬀects in
MS patients [37]. These eﬀects have been ascribed to the
fact that saturated fat forms aggregates that may be not
capableofenteringthesmallestcapillaries[38].Obstructions
ofthe capillaries may contribute toMS and otherdiseases. In
addition saturated fats decrease membrane ﬂuidity, lead to
thesynthesis ofcholesterol,activate theCD14/TLR4receptor
complex and favor the formation of TNF-α.A ss h o w n
in Figure 5, hypercaloric diets rich in saturated lipids and
lipogenesis favor several human diseases.
It is becoming clear now that the inﬂuence of fat on cells
is more direct: is controlled at transcriptional level [25], and
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Figure 5: Metabolic patterns and diseases correlated with lipogen-
esis.
inﬂuences gene expression, cell metabolism, and cell growth,
and diﬀerentiation [39].
4.2. Cow Milk, MFGM Proteins, and Molecular Mimicry
in MS. MS is believed to be an autoimmune disease.
Environmental (either microbial or dietary) factors can
be associated with autoimmunity and myelin breakdown
by molecular mimicry, that is, the amino acid homology
between the autoantigen and microbial or dietary peptides
[40]. According to this hypothesis, molecular mimicry
may disrupt immunological self-tolerance to CNS myelin
antigens in genetically susceptible individuals.
The best example of potential molecular mimicry
between myelin autoantigens and dietary proteins is given
by cow’s milk. The hypothesis of a link between milk
consumption and MS has been taken into consideration
sincethemidof1970s[41,42].Later,epidemiologicalstudies
gave support to this hypothesis [43].
ThemilkproteinsthatcouldbedetrimentalinMSarethe
proteinsofthemilkfatglobulemembrane (MFGMproteins)
[44]. The MFGM proteins account for only 1-2% of the total
protein fraction, and for this reason they are not relevant for
their nutritional value [45].
The protein which is most frequently suspected of the
association with MS is butyrophilin (BTN), the most repre-
sentative MFGM protein. BTN belongs to the Ig superfamily
and is very similar to MOG, the myelin oligodendrocyte
glycoprotein, one of the candidate autoantigen in MS [26].
BTN inhibits the MOG-induced experimental autoimmune
encephalomyelitis (EAE), but also induces inﬂammatory
responses in the CNS, when injected alone into animals,
and stimulates in vitro MOG-speciﬁc T cell responses [46].
Antibody cross-reactivity between MOG and BTN has been
observed in MS [47, 48]. Antibodies against BTN and
other MFGM proteins have been detected also in two other
diseases: autism[49]andcoronaryheart disease(CHD)[50].
The MFGM proteins might have detrimental eﬀects on
health also because they are associated to milk saturated
fat, another possibly deleterious dietary component. On
these grounds, we have introduced the concept that the
consumption of the MFGM proteins by MS patients should
be discouraged [44]. Diﬀerent is the opinion of Spitsberg
(2005) who reviewed the intake of MFGM proteins and milkAutoimmune Diseases 5
fat and recommended them for their potential nutraceutical
value [51]. However, reports on the relationship between
human health and cow milk do not substantiate such an
assertion, at present.
5.DietaryMoleculesPromoting
the Wellness ofMS Patients
5.1. Bioactive Natural Compounds for the Complementary
Treatment of MS. Speciﬁc bioactive dietary molecules could
counteract the eﬀects of microbial agents and downregulate
the expression of inﬂammatory molecules. There are indeed
several natural compounds which are able to interfere with
cell signaling and counteract oxidative stress, angiogenesis
and the production of inﬂammatory molecules which are
associated with MS. Among them, the most important
compounds are dietary molecules such as polyphenols and
carotenoids from vegetables, polyunsaturated fatty acids
(PUFA)from ﬁsh, vitamin D, and elements such as selenium
and zinc.
5.1.1. Antioxidant Dietary Molecules: Polyphenols and Car-
otenoids. Polyphenols and carotenoids are bioactive mol-
ecules found in vegetables, fruits, wine and other fruit-
based beverages, spices, and herbs. These dietary molecules
are well known for their antioxidant activity, but recent
ﬁndings indicate that they may have additional properties
independent of their roles as antioxidants and radical
scavengers (Figure 6).
The rationale for the use of natural antioxidants in MS is
based on the ﬁnding that oxidative stress and in particular
the generation of reactive oxygen species (ROS), is one of
the most important components involved in inﬂammation
and neuronal damage [52, 53]. On these grounds, the ad-
ministration ofappropriatedosesofantioxidants, suchasthe
dietary polyphenols and carotenoids, could be very useful to
restore the right balance between ROS generation and their
destruction.
Polyphenolsincludeﬂavonoidsand nonﬂavonoidsmole-
cules(Figure 7). Flavonoids,the most abundant polyphenols
in plants, are more than 8000 diﬀerent compounds which
have in common the structure of diphenylpropanes (C6-
C3-C6) with two benzene rings separated by a linear three-
carbon chain forming an oxygenated heterocycle.Flavonoids
can be divided into various classes: ﬂavanols (catechin,
epigallocatechin), ﬂavones (luteolin, apigenin), ﬂavanones
(naringenin, hesperidin), ﬂavonols (quercetin, myricetin),
isoﬂavones (daidzein, genistein) and anthocyanidins (cyani-
din, malvidin) [54, 55].
Nonﬂavonoids are hydroxycinnamic or phenolic acids
(caﬀeic acid, ferulic acid, including curcumin, a diferuloyl-
methane), lignans (secoisolariciresinol), stilbenes (resvera-
trol). They have only one or two phenolic rings.
Alternatively, polyphenols can be divided into four
diﬀerent classes: (1) those containing the pyrocatechol unit
(1,2 benzene diol) (hydroxytyrosol, caﬀeic acid, curcumin);
(2) those containing the resorcinol unit (1,3 benzene
diol) (resveratrol, genistein); (3) those containing both
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Figure 6: General biological activities of polyphenols & caroten-
oids.
the pyrocathecol and resorcinol units (quercetin, catechins,
anthocyanidins); (4) those containing the pyrogallol unit
(1,2,3 benzene triol) (Epigallocathechin) (Figure 6). This
classiﬁcation might are useful because diﬀerent chemical
groups might have diﬀerent eﬀects. For example, it has been
reported that catechols have antiinﬂammatory activity in
stimulated microglia and neutrophils and thereby be useful
for the treatment of neurodegenerative diseases [56, 57].
The most important polyphenols are quercetin (QRC),
resveratrol (RSV), curcumin (CRC); hydroxytyrosol, cate-
chins, daidzein, genistein. Among the carotenoids the most
important is lycopene. They often have a complementary
activity as antioxidants and radical scavengers.
Quercetin is found in onion, apple, citrus, and wine
[58]. QRC occurs mainly as glycoside, with a sugar group
bound to one of the hydroxyl groups of the ﬂavonol. QRC
has antiinﬂammatory, immunomodulating and antiviral
properties, reduces the proliferation of peripheral blood
mononuclear cells(PBMCs) and decreases the productionof
IL-1β,T N F - αand MMP-9. These eﬀectsare additive to those
of IFN-β [59].
QRC passes the BBB [60], inhibits myelin phagocytosis
byblockingtheROSreleasedfromthemacrophages[61]and
inhibits the expression of inﬂammatory cytokines through
inhibition of NF-κB[ 62]. Furthermore, QRC inhibits angio-
genesis[63],reducestheneutrophildependentinﬂammation
[57], and has neuroprotective eﬀects [64]. QRC inhibits
or ameliorates the Experimental Allergic Encephalomyeli-
tis (EAE) induced in SJL/J mice by mouse spinal cord
homogenate [65]. Apparently, QRC is not toxic [66], but its
oxidation product, quercetin quinone (QQ), which is very
reactive towards protein thiols and glutathione, could have a
toxic eﬀect [67].
Resveratrol is found in red wine, chocolate, peanuts,
berries, and black grapes. RSV is glucuronated in the
liver and absorbed in this form mainly in the duodenum.
Metabolic modiﬁcation of RSV is inhibited by QRC. Only
a few unmodiﬁed RSV molecules are absorbed. RSV has
a neuroprotective eﬀect and ameliorates MOG-EAE in
C57BL/6 mice [68].
RSV has anticarcinogenic, antiinﬂammatory, and es-
trogenic activities and allows cardiovascular protection,
free-radical scavenging, inhibition/induction of apoptosis,6 Autoimmune Diseases
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and inhibition of platelet aggregation. Depending on its
concentration, RSV mediates cell death of a variety of cells
by necrosis or apoptosis downregulating targets such as NF-
κB, AP-1, cyclins, STAT 3, and others, and upregulating
cytochrome c, caspases, cathepsin D, p53, JNK, and others.
RSV acts as a nonsteroidal antiinﬂammatory molecule and
inhibits the production of TNF-α,I L - 1 α,I L - 1 β,I L - 6 ,I L -
8, IL-18, MMP-9, VEGF, COX-2, 5-lipoxygenase, and ROS.
[69, 70].
Moreover, RSV activates the sirtuins, a family of histone
deacetylases, particularly SIRT2, and PPAR-α/γ [71].
Curcumin (CRC) is the yellow pigment present in curry
powder. Among its many biological properties, the most
important in the present context are its antiinﬂammatory
properties and in particular the downregulation of NF-κB
and AP-1 [72].
Catechins are polyphenols found in green tea. They have
antiinﬂammatory and anticarcinogenic activity [73], inhibit
the activity of MMP-2, MMP-9 and MMP-12 [74]a n dt h e
intestinal absorption of lipids [75].
Lycopene is a carotenoid that is found in tomato, water-
melon, and pink grapefruit. As an antioxidant, it is two times
better than beta-carotene and 100 times better than vitamin
E and protects against cancer [76, 77].
Hydroxytyrosol is themain antioxidant found in oliveoil
and a very eﬃcient scavenger of free radicals [78].Autoimmune Diseases 7
Soy ﬂavonoids as genistein downregulate proimatory
cytokines and ameliorate MOG-EAE symptoms in C57BL/6
mice [79].
Thiol-containing compounds such as alpha-lipoic acid
(ALA), glutathione and N-acetylcysteine (NAC) might be
eﬀective as oral supplements in the complementary treat-
ment of MS. ALA has immunomodulating eﬀects, stimulates
the production of cAMP, inhibits the synthesis of IFN-
gamma and adhesion molecules [80], is eﬀective in the
treatment of EAE [81], aﬀects T cell migration into CNS
and stabilizes blood-brain barrier integrity [82]. Studies in
patients with multiple sclerosis with oral supplements of
lipoic acid are underway to assess the right dosage of this
thiol compound [83]. NAC pass through the BBB and, like
glucorticoids and interferons, is able to protect it against
inﬂammation[84].ALA,NAC,andglutathionecouldbeuse-
ful to reduce the possible toxic eﬀect of quercetin quinones
described above. Other useful compounds with antioxidant
activity and a possible role as dietary supplements are:
melatonin, vitamin. E, selenium, vitamin C.
Vitamin D is another candidate for the environmental
eﬀects in MS etiology [85–87]. Indeed, the geographic
distribution of MS parallels that of the regions with minor
exposure to sunlight and lower availability of vitamin D
in the population. Accordingly, patients with MS are often
deﬁcient in vitamin D. At present, vitamin D represent,
the most promising natural molecule for the treatment
of autoimmune diseases and MS. Direct gene-environment
interaction of vitamin D and its immunomodulatory role
in the nervous system may represent the key for disease
prevention,butitsroleiscomplexanditisnotyetsuﬃciently
clear how it exerts a protective eﬀect.
Vitamin B12 is useful in EAE [88]. Selenium, a con-
stituentofselenoproteins, is considereda dietary antioxidant
that could be useful in the treatment of chronic diseases,
but its supplementation on long-term basis in healthy
individuals is strongly questioned. It is well absorbed as
selenomethionin or selenocysteine [89].
5.2. Unsaturated Fatty Acids from Vegetables, Sea Food and
Fish Oil. Unsaturated vegetable oils are the alternative to
saturated animal fat. Olive oil, in particular, should be
preferred to seed oils for its optimal ratio between saturated
and unsaturated fat. Olive oil contains the antioxidant
hydroxytyrosol and the omega-9 (n-9) monounsaturated
oleic acid. Vegetable oils contain also the essential fatty
acids (EFA) linoleic acid (n-6) and linolenic acid (n-3).
n-6 and n-3 fatty acids have opposing eﬀects and their
intake in the diet should be equivalent [90]. However,
in Western diets the n-6/n-3 ratio is increased 6/15-fold-
and this causes a greater incidence of cardiovascular and
inﬂammatory diseases. Indeed, the n-6 fatty acid linoleic
acid leads to the production of the 20:4 arachidonic acid
(AA),which istheprecursorofproinﬂammatory eicosanoids
such as prostaglandins (2-series), leukotriens (4-series), and
tromboxanes (2-series). Synthesis of these eicosanoids is
favored by insulin and inhibited by aspirin, but also by the
n-3 long chain polyunsaturated fatty acids (PUFAs), that
is, eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA), produced from the n-3 linolenic acid.
DHA is present at high concentration in the brain but
its levelsdecrease dramatically in MS patients. Both EPA and
DHA are found in high proportion in oily ﬁsh and ﬁsh oil
and show remarkable antiinﬂammatory, antithrombotic and
immunomodulating activities which are comparable with
statins. They also exert a number of neuroprotective eﬀects
and have a therapeutic value in several neurological diseases
[91–93].
n-3 PUFAs exert important eﬀects on gene expression.
They inhibit the transcription factors NF-κB, LXR and
SREBP-1c (the sterol regulatory element binding protein 1c)
and activate the nuclear receptors PPAR. As a result, n-3
PUFA decrease inﬂammatory processes and the synthesis of
fatty acids, but increase fatty acid oxidation [90]. On these
grounds, dietary n-3 EFA should prevail over n-6 EFA in
inﬂammatory diseases such as MS.
In LPS-activated rat microglial cells, ﬁsh oil inhibits the
expression of MMP-9, an important mediator of neuroin-
ﬂammation involved in myelin breakdown [94], in a similar
wayas IFN-betadoes[95].LikeIFN-beta,EPAand DHAalso
inhibit the formation of IFN-gamma. DHA also increases
the levels of tissue inhibitor of metalloproteinase-1 (TIMP-
1) [96].
Moreover, n-3 PUFA signiﬁcantly decreased MMP-9
levels in relapsing-remitting MS (RR-MS) [97], and other
few clinical trials indicate that n-3 PUFA may represent a
good complementary treatment in the course ofMS [98, 99].
Fish oil has been also found to improve motor performances
in healthy rat pups [100].
Seeds oils, from sunﬂower, corn, soy bean, and sesame,
contain more n-6 fatty acids (FAs) than n-3 FAs, and their
assumption should be limited in MS, in order to limit the
extent of proinﬂammatory eicosanoid production. Coconut
oil has a high content of saturated FAs. It is useful to
know that the intake of PUFA should be integrated with
antioxidants.
Hydrogenated FAs, found in margarine and othertreated
fat, are trans FAs and not cis FAs, like the natural ones,
and interfere with PUFA metabolism. Similarly, the frequent
intakeoffried shouldbeavoided,asfry causestheconversion
of cis FA in trans FAs.
5.3. Multiple Dietary Supplements. As indicated above,
bioactive natural products have a pleiotropic nature and
act on several and diﬀerent targets in the cell. Moreover,
antioxidants have diﬀerent redox potentials and use diﬀerent
mechanisms as radical scavengers. On these grounds, it can
be expected that an appropriate combination of some of
them may allow a synergistic eﬀect at low concentrations
and this may decrease the risk of toxicity [101]. Forexample,
polyphenols act mainly as antioxidants but their oxidation
may produce oxygen radicals and quinones which are toxic
[102].
A cocktail of polyphenols diﬀering in antioxidant capac-
ity and in the action on cellular targets can cover a large
spectrum of activities, in particular in combination with8 Autoimmune Diseases
n-3 PUFA. The utility of multiple dietary supplements
administration hasbeenshown inrecentexperimentalworks
[70, 103–105].
5.4. Calorie Restriction (CR). Diet does not mean only the
intake of bioactive dietary compounds. The most prominent
aspect that can augment the risk of chronic diseases is
energy intake: excessive calorie intake increases the risk.
Calorierestriction, obtainedeitherbydecreaseinfoodintake
or intermittent fasting (“every-other-day fasting”), protects
against neurodegenerative disease models and might be
eﬀective in slowing the progression of MS [106, 107]. CR
decreases the extent of oxidative damage and its eﬀects can
be mimicked by RSV.
5.5. The Role of Insuline in MS. Excessive calorie intake
increases the production of free radicals and inﬂammation.
Moreover, a meal rich in carbohydrates increases insulin
levels which stimulates lipogenesis and activates the enzyme
5-delta-desaturase (inhibited by EPA) which forms the
n-6 PUFA arachidonic acid (AA) from dihomo-gamma-
linoleic acid (DGLA). AA forms the eicosanoids involved in
inﬂammation.
5.6. Physical Exercise. In general, endurance exercise exerts
beneﬁcial eﬀects on health by targeting the AMP-activated
p r o t e i nk i n a s eA M P Ka n dt h eA M P K - P P A Rd e l t ap a t h w a y .
AMPK plays a key role in energy balance in the cell and
leadstosuppression ofATP-consuming anabolic pathwaysas
lipogenesisandinductionofATPformingcatabolicpathways
asfattyacidoxidation.AMPKisatargetofadipokines(leptin
and adiponectin) and regulate food intake, body weight,
as well as glucose and lipid homeostasis. RSV and AMPK
agonists can mimic and enhance the eﬀectsoftraining [108].
Exercise training induces a decrease in plasma leptin levels
and a reduction in geneexpression ofleptin receptorsin liver
[109]. The AMPK system appears to be downregulated in
EAE, and AMPK agonists and metformin, a drug used to
treat diabetes, attenuate the disease [110, 111].
6.Discussion
MS is a complex, multifactorial disease and nutrition is an
environmental factor possibly involved in its pathogenesis.
However, the role of nutrition in MS is at present completely
disregarded both in treatment and study of MS, and MS
therapy is not associated to a particular diet.
In thisarticle wehavetried toanswer tosome fundamen-
tal questions regarding the relationship between nutrition
and MS.
The ﬁrst question is whether nutritional habits really
mighthavesomething todowithMS.The 2008WHOreport
clearly indicates that MS has a geographical distribution
corresponding to countries with hypercaloric, high-fat/high-
carbohydrate diets and reduced exposure to ultraviolet
sunlight. Both diet and sunlight exposure may in fact explain
the inﬂuence of migration in young age on the course of the
diseaseandtheloweravailabilityofvitaminDinMSpatients.
Dietary habits are not relevant per se but, as shown in
Figure 2, hypercaloric diets promote the synthesis of fat and
inﬂammatory molecules. Accordingly, a study of the North
American Research Committee on Multiple Sclerosis has
recently found that a quarter of the patients were obese, and
31.3% were overweight [112]. On these grounds, a low calo-
rie (1700 kcal/day), low-fat diet, based on the consumption
of vegetables, fruit and ﬁsh, if possible varied (multicolored)
and distributed ﬁve times the day, should represent in the
future an important complementary treatment in the course
of MS in addition to pharmacological therapy.
The second question we tried to answer in this paper was
to assess at molecularlevelhow dietand dietary supplements
may ameliorate the course of MS and improve the wellness
of MS patients. As shown here, calorie restriction, physical
exercise, dietary antioxidants from vegetables and fruits, as
well as polyunsaturated fatty acids from ﬁsh, are able to
counteract the inﬂammatory responses associated to MS
by downregulating nuclear receptors, transcription factors,
and enzymes involved in the proimatory processes. For this
reason, the interest in natural bioactive compounds, mainly
belonging to the class of polyphenols and to n-3 PUFA, as
coadjuvants in the treatment of chronic diseases is increasing
very rapidly.
In particular, recent data are showing that polyphenols
(i) downregulate the expression of a number of enzymes and
molecules (5-LOX, COX-2, iNOS, MMP-9, IL-8, IL-6, TNF-
α, IL-12 and adhesion molecules such VCAM-1 and ICAM-
1); (ii) upregulate the PPARs, in particular α and γ,a n d
Nrf2; downregulate NF-κB, AP-1, STAT-1,3,5; (iii) inhibit
severalproteinkinases(IKK,EGFR,HER -2,AKT ,J AK-2,Src,
JNK,PKA,PKC,TYK-2...)andenzymessuchasGST ,GSH-
px, uPA, FTPase, xanthine oxidase, hemeoxygenase. In most
cases polyphenols and n-3 PUFA share common eﬀects. All
these data indicate that natural bioactive molecules might
be able to inﬂuence the course of MS and ameliorate the
wellness of MS patients through molecular mechanisms
that appear plausible and convincing. Molecular targets and
mechanisms of action of natural and pharmacological drugs
are often the same. This means that we can expect that they
can act in synergy.
We have recently shown that ﬂavonoids and non-
ﬂavonoids inhibit MMP-9 levels with diﬀerent mechanisms
possibly related to their diﬀerent structure: ﬂavonoids, such
asquercetinandthecathechinsfromgreentea,inhibitMMP-
9 directly; while non ﬂavonoids, such as resveratrol and
tyrosol/hydroxytyrosol from olive oil, inhibit its expression
[113].
Based on the investigations carried out in cancer and
rheumatoid arthritis, polyphenols seem to have the potential
for their treatment, as well as of various chronic inﬂam-
matory diseases, but very few clinical trials have yet been
done with the pure compounds. At present, only the studies
on EAE can give some indication on the uselfulness of the
treatment withantioxidantsinMS.Withtheexceptionofthe
study ofVerbeek et al. [114], all antioxidants tested appear to
exert a healthy eﬀect on the disease.
Data on the bioavailability of polyphenols in humans
are not yet suﬃcient and bioavailability of polyphenols is,Autoimmune Diseases 9
in any case, very low. In foods, ﬂavonoids are mainly gly-
cosylated and phenolic acids are in the form of esters and,
after their conversion to aglycons, they are sulphated, glu-
curonidated or methylated in our body [115, 116]. This
makes diﬃcultto determine theoptimal dose ofpolyphenols
requiredtoachieveprotectiveeﬀectsandavoidtheformation
of toxic compounds.
Moreover, it is not clear whether these bioactive
molecules should be taken alone or in combination and
which is their optimal concentration or the best ratio. The
recommended daily allowances (RDAs) of polyphenols are
not yet known and it is necessary to assess the lowest
concentration, which is eﬀective in counteracting cell acti-
vation without the formation of high amounts of toxic
oxidation products. An excess of antioxidants can indeed
be deleterious. Protection from quinones and other toxic
compounds can be achieved by –SH containing products
such as alfa-lipoic acid and N-acetylcysteine.
At present, polyphenols are taken in the order of mg
and PUFA in the order of grams, but decisions concerning
the dosage of dietary supplements and their combination
should be taken in studies in vitro and in vivo experiments.
In particular, clinical studies with polyphenols, n-3 PUFA
and vitamin D and other antioxidants should be taken into
consideration for their eﬀectiveness in MS patients.
In conclusion, given that diet and dietary supplements
are not pharmacological drugs and cannot replace the
conventional MS therapy, they can concur to the ame-
lioration of the wellness of MS patients. As shown in
this review paper, the fundamental molecular prospect for
a nutritional intervention in inﬂammatory, autoimmune
diseases as MS, is given by the ability of some natural
food components to modulate cell metabolism and in
particular the activity of ligand-dependent nuclear receptors
and transcription factors, which are able to downregulate
inﬂammatory and autoimmune processes. Among them,
the most promising targets of dietary molecules are the
PPAR, in particular PPAR-gamma, that have a pivotal role in
regulating both metabolism and inﬂammation [117]. Future
research will clarify whether bioactive dietary molecules
could also inﬂuence the process of diﬀerentiation of mature
oligodendrocytes and promote remyelination.
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